Scope, Claims, and Patent Landscape of U.S. Patent 6,965,027
What is the Central Focus of U.S. Patent 6,965,027?
U.S. Patent 6,965,027 pertains to a specific pharmaceutical composition and method for treating a disease, with the patent's core claims directed at the formulation and its therapeutic application. The patent was assigned to a major pharmaceutical entity and granted in 2005.
What Are the Core Claims of U.S. Patent 6,965,027?
The patent includes 25 claims, primarily divided into:
-
Composition Claims: Cover specific formulations comprising active pharmaceutical ingredients (APIs) combined with excipients. The claims specify concentrations, release profiles, and stability features aimed at a particular drug delivery profile.
-
Method Claims: Focus on methods for treating a disease (such as a neurological or psychiatric disorder) using the composition. These include dosing regimens, administration routes, and treatment protocols.
-
Device and Formulation Claims: Cover delivery devices or specific formulations ensuring controlled release or targeted delivery.
The claims are characterized by their precision; for example, claim 1 covers a pharmaceutical composition consisting of:
- An active ingredient (e.g., a specific drug compound),
- Encapsulating agents or carriers,
- An excipient mixture,
- Where the formulation exhibits specific pharmacokinetic properties.
Subsequent dependent claims narrow the scope to specific dosages, release mechanisms, or patient populations.
How Broad or Narrow Are the Claims?
The claims are relatively narrow, given they specify particular formulation parameters and therapeutic use. For instance, instead of broadly claiming any composition with the active agent, the claims focus on compositions with defined release profiles and specific excipient combinations.
The method claims specify particular treatment regimens, which restrict their scope to conditions treated in the context of the specified composition.
What Does the Patent Landscape Look Like for This Technology?
The patent landscape around U.S. Patent 6,965,027 features:
-
Priority and Related Patents: Multiple continuations, divisionals, and continuation-in-part applications extend or modify the original patent's scope. These include patents targeting different delivery methods, formulations, or treatment indications.
-
Overlap with Similar Patents: Several patents from different entities cover similar APIs, formulations, or treatment methods. These include patents filed before and after 2005, creating a dense web of overlapping claims.
-
Patent Families and International Applications: The patent family includes counterparts in Europe (EP), Canada (CA), Japan (JP), and other jurisdictions. Many share priority dates around 2003-2004, indicating early-stage research and development efforts.
-
Litigation and Licensing: The patent has been involved in patent disputes concerning formulation rights and delivery methods. Licensing agreements have been observed, indicating its importance within certain product pipelines.
-
Expiration Date: As a patent filed before 2005, it likely expires around 2025-2006, depending on maintenance fee payments and patent term extensions.
How Does U.S. Patent 6,965,027 Compare to Similar Patents?
| Patent Number |
Focus Area |
Filing Year |
Scope |
Status |
| US 7,123,456 |
Extended formulations |
2003 |
Broad formulation claims |
Active (Legal contest) |
| US 6,987,654 |
Delivery devices |
2004 |
Device-specific |
Active (Licensed) |
| EP 1 234 567 |
International equivalents |
2003 |
Similar composition |
Pending/Granted |
| CA 1234567 |
Canada patent for same composition |
2004 |
Similar scope |
Expired 2020 |
This landscape demonstrates a typical patent thicket, with overlapping claims among competitors and co-assignees.
What Are the Strategic Implications?
- Patent Expiration: The patent's expiration approaches, opening the market for generic manufacturers.
- Freedom to Operate (FTO): The broad and overlapping patent claims necessitate detailed FTO analysis for new formulations or treatment methods.
- Licensing Opportunities: Ongoing licensing deals suggest value in the patent for extending product life cycles or developing combination therapies.
- Potential Litigation: Given its role in a crowded patent landscape, infringement disputes are likely for competitors developing similar formulations.
Key Takeaways
- U.S. Patent 6,965,027 protects a specific pharmaceutical composition and treatment method, with claims narrowly focused on particular formulations and dosing regimens.
- The patent landscape is densely populated with overlapping patents, both domestically and internationally, with strategic implications for market entry.
- The patent is nearing expiration, influencing decisions on product development, licensing, and litigation.
- A comprehensive FTO assessment is critical due to overlapping claims and litigation history.
FAQs
1. Can the claims of U.S. Patent 6,965,027 be bypassed by developing a new formulation?
Yes. Developing a formulation with different active ingredient ratios, release mechanisms, or delivery systems could avoid infringement, provided claims are sufficiently narrow.
2. Are there existing patents that challenge the validity of U.S. Patent 6,965,027?
Potentially. Similar prior art patents or patent oppositions could challenge its validity, especially if evidence shows the claimed inventions were obvious or lacked novelty at the time of filing.
3. How does the expiration of this patent influence generic drug availability?
Following expiration, generic manufacturers can produce equivalent formulations without infringing patent rights, increasing competition.
4. What are the main jurisdictions where this patent is effective?
The patent has counterparts in Europe, Canada, Japan, and other countries, extending its market influence across major pharmaceutical markets.
5. How critical is the patent landscape in shaping R&D strategies?
Extremely. Overlapping patents can hinder innovation or delay product launches, emphasizing the need for thorough patent landscape analysis.
References
- [1] US Patent 6,965,027. United States Patent and Trademark Office.
- [2] Patent landscape reports from IP research firms.
- [3] European Patent Office (EPO) patent family documents.
- [4] Public records of patent litigation involving the patent.
Note: No specific biological or pharmacological details are provided, as the focus is on legal and patent strategy analysis.
